TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Biopsy-proven CTCL, MF subtype~* Clinical stage IB, II, or III, with staging based on screening assessments~* Minimum mSWAT score of 10 at screening~* Receipt of at least one prior therapy for CTCL~Key Exclusion Criteria:~* Previous enrollment in a cobomarsen study~* Prior therapy with vorinostat or other HDAC inhibitors, or contraindication to an HDAC inhibitor~* Sézary syndrome or mycosis fungoides with B2 involvement, defined as documented history of B2 and/or B2 staging at screening~* Evidence of large cell transformation~* Lymph node involvement at screening, unless radiologically or histologically confirmed to be nonmalignant~* Visceral involvement related to MF at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cobomarsen (Type: EXPERIMENTAL): Cobomarsen will be administered by intravenous 2-hour infusion at a dose of 282 mg on Days 1, 3, 5, 8, and weekly thereafter
- Vorinostat (Type: ACTIVE_COMPARATOR): Vorinostat will be administered orally at a dose of 400 mg (four 100-mg capsules) once daily with food, at approximately the same time each day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females aged ≥ 18 years~* Coronary artery disease with a clinically diagnosed peripheral neuropathy~* Willing and able to provide signed informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization~* Willing and able to comply with the requirements of the protocol and follow directions from the clinic staff~Exclusion Criteria:~* History of allergy or intolerance to ranolazine~* Any condition or concomitant medication that would have precluded the safe use of ranolazine as outlined in the prescribing information sheet (see Appendix E)~* In the judgment of the investigator, any clinically-significant ongoing medical condition that might jeopardize the patient's safety or interfere with the absorption, distribution, metabolism or excretion of the study drug~* In the judgment of the investigator, clinically-significant abnormal physical findings during screening (excluding the patient's peripheral neuropathy condition)~* Use of any experimental or investigational drug or device within 30 days prior to screening~* Pregnant or breast feeding, or (if premenopausal), not practicing an acceptable method of birth control (as detailed in Inclusion Criterion 4)~* Had received prior treatment with, or investigational exposure to, ranolazine within 7 days prior to randomization~* Clinically significant hepatic impairment~* Had end-stage renal disease requiring dialysis~* Psychological or addictive disorders (not limited to, but including drug and/or alcohol dependency) that may have precluded patient consent or compliance, or that may have confounded study interpretation~* Positive pregnancy test at Baseline (pre-randomization, Day 0)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo-Ranolazine (Type: EXPERIMENTAL): Participants were randomized to receive placebo to match ranolazine during Weeks 1 to 6, then ranolazine during Weeks 7 to 12.
- Ranolazine-Placebo (Type: EXPERIMENTAL): Participants were randomized to receive ranolazine during Weeks 1 to 6, then placebo to match ranolazine during Weeks 7 to 12.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hypnosis as a Potentiation Technique for the Interventional Treatment of Chronic Lumbar Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent and signature of the declaration of consent ;~* Patient suffering from chronic lumbar pain (\> 3 months)~* Indication for a facet block ;~* Good ability to speak and understand French.~Exclusion Criteria:~* Previous facet block for the same indication ;~* Unability to understand or speak French ;~* Unability to understand the written or oral instructions necessary to the protocol application ;~* Acute or severe psychiatric decompensation and/or acute psychosocial distress ;~* Complex psychosocial situation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: OTHER): There will be only one arm for this pilot study. All participants will follow 4 hypnosis sessions, and then the facet block.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Oral Nutritional Supplement in Reducing Surgical Site Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled for elective lower limb revascularization surgery~* patients aged \>18 years.~Exclusion Criteria:~* Patients unable to provide informed consent,~* emergency cases,~* seriously ill patients/unconscious patients,~* chronic renal disease,~* known inflammatory bowel disease,~* known lactose intolerance and not using lactase,~* known galactosemia,~* pregnancy,~* cows milk allergy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arginine enriched oral nutritional supplement group (Type: EXPERIMENTAL): Patients randomised to the oral nutritional supplement group will continue their normal diet. In addition, this group will commence taking oral nutritional supplement twice daily 5 days prior to surgery and continued for 4 weeks post surgery. Intake of nutritional drink will be suspended during their fasting period prior to surgery and will commence once surgery is completed and group are able to tolerate food post surgery. Wound examination will take place at 1 and at 4 weeks post surgery by the tissue viability nurse specialist who will be blinded to the treatment. Patient adherence to the study protocol with the nutritional supplement regimen will be recorded daily by the patient for four the four weeks the supplement is provided.
- Control (Type: NO_INTERVENTION): This group will continue on their normal diet before and after surgery. Normal diet will be suspended during their fasting period prior to surgery and will re commence once surgery is completed and group are able to tolerate food post surgery. Wound examination will take place at 1 and at 4 weeks post surgery by the tissue viability nurse specialist who will be blinded to the treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Glomerular Filtration Rate-Estimating Equations During Use of Direct Oral Anticoagulants in Elderly Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients with non-valvular atrial fibrillation -treated with dabigatran, rivaroxaban or apixaban - patients affiliated to national social health system -patients who agreed to ethical concerns of the study~Exclusion Criteria:~Patients with consultation or hospitalization that made impossible a veinous punction at the steady state residual concentration time -Patients under guardianship or trusteeship

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Blood sample (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Linköping University Relational and Interpersonal Psychotherapy Project

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Major Depressive Disorder (DSM-IV)~* Hamilton Depression Rating Scale (17-item version) score 20 or greater~Exclusion Criteria:~* Any psychotic disorder~* Substance abuse~* Organic brain disorder

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- IPT (Type: ACTIVE_COMPARATOR): Interpersonal Psychotherapy for Major Depressive Disorder
- BRT (Type: EXPERIMENTAL): Brief Relational Therapy adapted for treatment of Major Depressive Disorder

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: In Vitro Follicle Activation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women diagnosed with primary ovarian insufficiency (POI), seeking pregnancy and eligible for IVF at Colorado Center for Reproductive Medicine (Lone Tree, CO).~* Patients can be of any race, culture, sexual orientation or ethnicity.~Exclusion Criteria:~* Minors are excluded from participation in this study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- In Vitro Follicle Activation (IVA) (Type: EXPERIMENTAL): Ovarian tissue will be removed and cultured in vitro with compounds to activate dormant follicles. Following activation, ovarian tissue will be auto-grafted and the patient monitored for follicular growth.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: STARR Trans-anal Resection Versus Vaginal Rectocele Repair Using Elevate: Effects on Defecatory Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patient is not under any type of guardianship~* patient has a rectocele \> 3 cm during defecography~* patient has persistent defecatory troubles depite medical treatment (laxatives for at least 1 month) and an ODS score \> 10~* patient recieved information and signed the consent form~Exclusion Criteria:~* patient cannot read French~* patient has an asymptomatic rectocele~* patient with an enterocele at rest upon defecography, with opacification of the small bowel~* patient with non-rehabilitated anorectal asynchrony (anism)~* patient with anal incontinence, Wexner score \> 7~* patient has a rectal lesion~* patient has previously had rectal surgery including a colorectal anastomosis~* patient has previously had a surgery involving disection of the rectovaginal wall, except for myorraphy of relever muscles~* patient has previously had pelvic radiotherapy~* anal sphincter insufficiency detected by rectomanometry~* megarectum detected by rectomanometry and defecography~* granule transit anomaly: \> 70h~* exteriorized rectal prolapse~* rectovaginal fistule~* intestinal inflammatory disease~* anal stenosis~* anal or rectal tumor~* patient refuses to participate or refuses to sign consent~* patient is enrolled in another study~* contra indication for general or localized anesthesia~* patient does not have social security coverage

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- STARR arm (Type: EXPERIMENTAL): In this group of patients, the STARR transanal stapling system is used to treat the rectocele.
- Elevate arm (Type: ACTIVE_COMPARATOR): In this group of patients, a posterior Elevate mesh is placed transvaginally to treat the rectocele.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sleep and Endometrial Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* be women at least 18 years old~* have clinical indications of primary endometrioid adenocarcinoma of the endometrium~* be scheduled for staging surgery by laparotomy under standardized protocols~* have the ability to communicate in English sufficient for completion of study materials~* have no neuromuscular/ movement disorders (for actigraphy purposes)~* have no uncontrolled medical, sleep, endocrine or psychiatric illness (as determined by their attending physician as part of clinical care)~* have no ongoing use of medication known to affect sleep or wake function (e.g., hypnotics, benzodiazepines, antidepressants, anxiolytics, antipsychotics, decongestants, sedating antihistamines, beta blockers, corticosteroids)~Exclusion Criteria:~* have a history of previous or concomitant cancer~* have an estimated life expectancy of \< 6 months~* will be admitted to the hospital prior to the day of surgery~* are unable to complete study measures~* are unable to provide meaningful informed consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- zolpidem (Type: EXPERIMENTAL): Participants randomized to the zolpidem (intervention) group will receive the FDA approved dose of zolpidem, (10 mg for women \<65; 5 mg for women \> or = 65 years). For the purposes of this double-blind trial, zolpidem (e.g., Roxane Laboratories) pills will be placed without filler inside two-piece gelatin capsules (DBcaps, Capsugel) and packaged by the Investigational Drug Service (IDS) of the University of Pittsburgh Cancer Institute. During their presurgery visit (visit 1), participants will be provided with their capsule and instructed to take it by mouth immediately before bedtime the night before surgery.
- sugar pill (Type: PLACEBO_COMPARATOR): Participants randomized to the sugar pill (control) group will receive placebo. For the purposes of this double-blind trial, placebo (sugar) pills will be placed without filler inside two-piece gelatin capsules (DBcaps, Capsugel) and packaged by the Investigational Drug Service (IDS) of the University of Pittsburgh Cancer Institute. During their presurgery visit (visit 1), participants will be provided with their capsule and instructed to take it by mouth immediately before bedtime the night before surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Imaging Tau in Alzheimer's Disease and Normal Aging

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 50 and older.~2. Meet criteria for either a) amnestic mild cognitive impairment (single or mixed domain) or mild Alzheimer's disease, or b) have no cognitive impairment, based on history, exam, neuropsychological testing, and consensus diagnosis. MCI and mild AD patients must have Clinical Dementia Rating scale score of 0.5 or 1. Unimpaired subjects must have Clinical Dementia Rating scale score of 0.~3. Subjects unable to provide informed consent must have a surrogate decision maker.~4. Written and oral fluency in English or Spanish.~5. Able to participate in all scheduled evaluations and to complete all required tests and procedures.~6. In the opinion of the investigator, the subject must be considered likely to comply with the study protocol and to have a high probability of completing the study.~Exclusion Criteria:~1. Past or present history of certain brain disorders other than MCI or AD.~2. Certain significant medical conditions, which make study procedures of the current study unsafe. Such serious medical conditions include uncontrolled epilepsy and multiple serious injuries.~3. Contraindication to MRI scanning.~4. Conditions precluding entry into the scanners (e.g. morbid obesity, claustrophobia, etc.).~5. History of kidney disease or presence of impaired kidney function based on laboratory tests at the screening visit.~6. History of liver disease or presence of impaired liver function based on laboratory tests at the screening visit.~7. Participation in the last year in a clinical trial for a disease-modifying drug for AD.~8. Inability to have a catheter in subject's vein for the injection of radioligand.~9. Inability to have blood drawn from subject's veins.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Cognitive impairment (Type: EXPERIMENTAL): Adults with Alzheimer's disease, preclinical Alzheimer's disease or impairment due to suspected non-Alzheimer's disease pathophysiology will receive 18F-THK- 5351 and/or lumbar puncture (optional).
- No cognitive impairment (Type: ACTIVE_COMPARATOR): Normal aging adults will receive 18F-THK- 5351 and/or lumbar puncture (optional).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Robot-based Tele-echography II - A Comparative Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Person registered with the French Social Security or benefiting from an equivalent health insurance system~* Person sent to hospital for thoracoabdominal high energy trauma~Exclusion Criteria:~* Ward of court or under guardianship~* Adult unable to express their consent~* Person deprived of freedom by judicial or administrative decision~* Person hospitalized without their consent~* Person under legal protection~* Person participating in another clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Robot-Based Tele-Echography (TER) (Type: EXPERIMENTAL): ultrasound performed according to the method Tele-Echography
- ultrasound method FAST (Type: ACTIVE_COMPARATOR): ultrasound performed according to the method FAST (Focused Assessment Sonography for Trauma)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Discogenic Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* MR imaging : MODIC 1or MODIC 2 changes limited to one single lumbar disc;~* X rays: normal disc height, no instability;~* Back pain for at least 3 months, without argument for another etiology;~* Mean pain on 5 days VAS ≥ 5~Exclusion Criteria:~* age \<18 years or \> 50 ; concomitant radicular pain ;~* psychiatric pathology that may modify the perception or the evolution of pain;~* MR imaging: multi-level discopathy, MODIC 3 changes;~* X ray: loss of disc height \> 50%, segmental instability;~* previous history of lumbar surgery with or without instrumentation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- DISCOGEL (Type: EXPERIMENTAL): Percutaneous intradiscal injection of Discogel
- conventional treatment (Type: ACTIVE_COMPARATOR): conventional treatment based on current guidelines regarding the management of discogenic low back pain, including but not limited to: medications (analgesics, NSAIDs, muscle relaxants), physical therapy, manual techniques, transcutaneous electrical nerve stimulation (TENS), blocks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility